March 17, 2026
In preclinical drug development, success is rarely determined by infrastructure alone. While facilities, equipment, and models are essential, the ultimate outcome of a program often depends on the people guiding the work. At Envol Biomedical, that responsibility falls to an experienced team of Study Directors—scientists who serve as the intellectual and operational leaders behind each program.
These individuals do far more than oversee timelines or coordinate laboratory activities. At Envol, Study Directors act as scientific partners to sponsors, bringing deep expertise, proactive communication, and hands-on leadership to every stage of a study. Their role reflects Envol’s broader philosophy: high-quality science requires high-quality leadership.
Building a Study Director Team Around Scientific Depth
Envol’s approach to building its Study Director team begins with a simple principle: the right leadership must combine scientific credibility with practical experience in translational research.
Rather than filling these roles with purely administrative managers, Envol prioritizes scientists with strong research backgrounds and real-world experience supporting drug development programs. Many of the Study Directors at Envol hold advanced medical or scientific degrees and have worked across multiple disciplines relevant to preclinical research, including pharmacology, toxicology, surgery, pathology, and translational medicine.
This depth allows them to do more than follow protocols. They understand the scientific questions driving each program and can actively help sponsors refine study design, interpret results, and troubleshoot unexpected outcomes. Their expertise ensures that studies are not simply executed—but thoughtfully guided.
In a field where timelines are tight and regulatory expectations are high, this level of scientific leadership becomes a critical advantage.
A Client-Facing Model That Keeps Sponsors Close to the Science
One of the defining aspects of Envol’s Study Director model is how directly they interact with sponsors.
At many CROs, sponsors communicate primarily with project managers or account representatives, with scientific leadership remaining largely behind the scenes. Envol takes a different approach. Study Directors serve as the primary scientific point of contact for clients, maintaining regular dialogue throughout the life of a study.
This direct connection allows sponsors to engage with the people who are closest to the data and the experimental process. Questions can be addressed quickly, study adjustments can be discussed in real time, and decisions can be made with full scientific context.
For sponsors navigating complex development programs, this level of transparency and accessibility provides both clarity and confidence.
Scientific Leadership That Drives Study Success
The responsibilities of a Study Director extend across every phase of a research program. From the earliest stages of study planning through data interpretation and reporting, they ensure that each program maintains scientific rigor and operational efficiency.
At Envol, Study Directors guide protocol development, coordinate with surgical teams and laboratory specialists, monitor study progress, and oversee data quality. When unexpected findings emerge—as they often do in translational research—the Study Director plays a central role in interpreting those results and advising sponsors on next steps.
Because they are embedded within Envol’s integrated research environment, they are able to collaborate closely with specialists across pharmacology, pathology, imaging, and surgical services. This coordination helps ensure that studies run smoothly while maintaining the scientific precision required for regulatory submissions.
In many ways, the Study Director functions as both the architect and steward of a study, ensuring that every component contributes meaningfully to the sponsor’s broader development goals.
Meet the Study Directors Behind Envol’s Research Programs
The strength of Envol’s leadership model is reflected in the individuals who serve in these roles. Each Study Director brings a unique combination of expertise, experience, and scientific perspective that supports the wide range of programs conducted at Envol.
Daniela Schwotzer, PhD, DABT, serves as Director of Toxicology and leads Envol’s Study Director team. With deep expertise in toxicology and regulated preclinical research, she plays a central role in maintaining scientific rigor across programs while mentoring and coordinating the broader Study Director group. Her leadership helps ensure that studies are designed and executed to meet the demanding expectations of regulatory science.
Reinier Espinosa, MD, serves as a Study Director and Director of Translational Sciences and Surgery. His medical training and experience in surgical and translational research enable him to bridge the gap between preclinical experimentation and clinical relevance. Reinier’s work is particularly valuable for programs involving advanced surgical models, device testing, and complex translational studies.
Arlet Hernandez, PhD, brings strong scientific training and experience in experimental research, contributing to study design, execution, and interpretation. With a degree in toxicology, her work helps ensure that studies generate clear and reliable data that sponsors can confidently use to guide development decisions.
Cagri Serkan Ansen, MD, combines medical expertise with hands-on experience in translational research models. His background allows him to provide important clinical context when evaluating therapeutic effects, helping sponsors better understand how preclinical outcomes may translate into future patient applications.
Yoel Chavez Lopez, MD, contributes medical insight and strong analytical expertise to Envol’s research programs. His ability to evaluate complex datasets and connect experimental findings with therapeutic objectives helps sponsors extract meaningful insights from their studies.
Rafael Vieira, DVM, brings veterinary expertise that is essential for conducting high-quality preclinical research involving animal models. His background in veterinary medicine supports both animal welfare and scientific rigor, ensuring that studies are conducted responsibly while generating reliable translational data.
Together, this team represents the multidisciplinary expertise that Envol has intentionally cultivated within its Study Director group.
A Leadership Model Designed for Modern Drug Development
As drug development programs become increasingly complex—particularly in areas such as biologics, gene therapies, advanced delivery platforms, and metabolic or neurological disease models—the need for strong scientific leadership in preclinical studies continues to grow.
Envol Biomedical has responded by building a Study Director team designed not only to manage studies, but to actively contribute to their success. Through deep scientific expertise, direct client engagement, and close integration with Envol’s broader research infrastructure, these leaders help ensure that each study generates meaningful, actionable insights.
For sponsors navigating the challenges of modern drug development, that level of partnership can make a significant difference.